AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Indivior PLC

Report Publication Announcement Nov 6, 2018

4923_rns_2018-11-06_823b8138-39b8-4526-a0ec-8f7330bd818e.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3892G

Indivior PLC

06 November 2018

Indivior Announces Upcoming Investor Events

Slough, UK, and Richmond, VA, 6 November 2018 - Indivior PLC (LON: INDV) today announced the following upcoming investor events:

Stifel 2018 Healthcare Conference, New York City:

On Tuesday, November 13th from 9:30 a.m. to 10:10 a.m. (local time) Shaun Thaxter, CEO, and Mark Crossley, CFO, will conduct a fireside chat with Max Hermann, Stifel Healthcare Analyst.

Indivior 2018 Capital Markets Day, New York City:

On Wednesday, December 5th from 9:00 a.m. to 12:30 p.m. (local time), Indivior senior management will review and present the Company's key business lines. Attendance for this event will require pre-registration, as space is limited. To register, please send an e-mail to [email protected].

A live webcast of both events, including any presentations, will be available on the "Investors" section of the company's website at www.indivior.com.

About Indivior

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavor, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-379-1033 or [email protected]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

MSCZELFBVFFEFBD

Talk to a Data Expert

Have a question? We'll get back to you promptly.